We are reading the FDA drug review.

So another week will end soon. Isn’t it a moment so fast? This is a signal of our precious signals for weekend plans. Our agenda is somewhat humble. We look forward to walking along with the official mascot, catching up with the growing reading list, and organizing around the castle. We also hope to hold another listening party with Mrs. Pharmalot, and will be included in the rotation. this,,, this,,, this,,, this and this. And how about you? Those in this pond still have time to report taxes. If you are concerned about rising prices or hide cash under some floor plates, it may be a good time to stock up the sun. Alternatively, you can adjust the noise by curling the binge clock in front of Teli. Well, spend a magnificent time no matter what you do. But be safe. Enjoy and meet soon. …

The US food and drug management staff who reviewed drugs and devices and inspected manufacturing factories were protected when the Trump administration was dismissed, and preserving some of the most important institution functions is likely to be affected.Stat explains. The source said that the reduction had a particularly significant impact on the ability to convene an expert advisory committee, the core part of the approval process. Another factor is that the Ministry of Health and Welfare’s officials are slowing the process of approving the new committee members. There is no advisory committee scheduled between February and May 5, and the organization will hold a meeting on research on opioid misuse. Last year, the institution held seven meetings during that period. Biologics Center is already slowing to submit a product that comes in as the employees who have allocated and distributed regulatory work disappeared.

Novartis plans to spend $ 23 billion to build and expand 10 facilities in the United States due to a new threat to the Trump administration’s drug import business.,,, Reuters To us. The company expects to build six new manufacturing plants, and some of which will create herbal ingredients as well as the new R & D sites of San Diego. New sites and expansion will be built for the next five years, and are expected to create more than 1,000 jobs for skilled workers such as engineers and scientists and 3,000 other employees and construction jobs. The pharmacy has not yet decided to build four new manufacturing plants, but two said that two used to produce certain cancer therapies will be built in Florida and Texas. In the next five years, the total investment in the United States is expected to be almost $ 50 billion.